Rapport Therapeutics Plunges After Pricing Dilutive Equity and Debt Offerings

Shares of Rapport Therapeutics (RAPP) plunged in morning trading, falling over 17% to $22.84 after the company announced the pricing of a large capital raise that investors viewed as significantly dilutive to existing shareholders.

Details of the Offering

Rapport priced a multi-part offering designed to raise substantial capital. The deal includes several components:

• An underwritten public offering of common stock priced at $21.00 per share, representing a roughly 24% discount to the previous day's closing price of $27.54.
• A concurrent sale of $150 million in 2.25% convertible senior notes due 2032, which introduces the risk of future share dilution upon conversion.
• A separate private placement agreement to sell approximately $30 million of common stock at the same $21.00 offering price.

The company expects to receive net proceeds of approximately $187.5 million from the public stock offering, $28.2 million from the private placement, and $145 million from the notes offering. The steep discount on the common stock immediately triggered a repricing of the stock across its entire float.

Strategic Rationale and Context

Ad

Rapport stated its intention to use the proceeds primarily to fund ongoing and planned clinical trials for its drug candidate, RAP-219. The company believes the combined capital will extend its operational runway through the end of 2029.

The timing of the offering follows a recent announcement that Rapport's Phase 2 study for RAP-219 in bipolar mania met its primary endpoint. However, the source noted that the drug's effect size fell short of levels targeted by the company and analysts. This earlier clinical news had propelled the stock higher, providing management a window to access capital markets, albeit at a cost to near-term shareholders.

Market Impact

The sell-off in Rapport's stock was company-specific, occurring while the broader S&P 500 and Nasdaq indices traded modestly higher. The sharp decline pushed the stock to an intraday 52-week low of $22.36, a stark reversal from its 52-week high of $52.93.

The combination of the deeply discounted equity sale and the future dilution risk from the convertible notes created significant selling pressure. The offerings, managed by Morgan Stanley, Leerink Partners, and Evercore ISI, are expected to close on or about October 30, 2026.